Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Down 55.4% in June

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 17,654 shares, a drop of 55.4% from the May 31st total of 39,619 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 100,034 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Get Otsuka alerts:

Read Our Latest Stock Analysis on OTSKY

Otsuka Stock Performance

Shares of OTCMKTS OTSKY opened at $33.91 on Monday. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The stock’s 50 day simple moving average is $34.44 and its 200 day simple moving average is $32.62. The company has a market cap of $36.43 billion and a price-to-earnings ratio of 14.31. Otsuka has a 12-month low of $21.68 and a 12-month high of $37.52.

Otsuka (OTCMKTS:OTSKY – Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The company had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Equities research analysts expect that Otsuka will post 1.98 EPS for the current year.

Otsuka Company Profile

(Get Free Report)

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.

Featured Articles

• Five stocks we like better than Otsuka
• As Stablecoins Keep Growing, These 2 Stocks Benefit
• Apple Just Handed These 4 Memory Stocks Their Best News of the Year
• Costco’s Secret Growth Engine May Be Running Out of Gas
• Why Alphabet’s Pullback May Be an Opportunity in Disguise

Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.